ICD-10-CM Code E85.89

Other amyloidosis

Version 2021 Billable Code

Valid for Submission

E85.89 is a billable code used to specify a medical diagnosis of other amyloidosis. The code is valid for the fiscal year 2021 for the submission of HIPAA-covered transactions. The ICD-10-CM code E85.89 might also be used to specify conditions or terms like aa amyloid nephropathy, aa amyloidosis, age-related amyloidosis, al amyloidosis, al amyloidosis, al amyloidosis, etc

Short Description:Other amyloidosis
Long Description:Other amyloidosis

Index to Diseases and Injuries

The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10 code(s). The following references for the code E85.89 are found in the index:


The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • AA amyloid nephropathy
  • AA amyloidosis
  • Age-related amyloidosis
  • AL amyloidosis
  • AL amyloidosis
  • AL amyloidosis
  • Amyloid light chain amyloidosis due to multiple myeloma
  • Amyloid myopathy
  • Amyloid nephropathy
  • Cerebral amyloid angiopathy
  • Cerebral amyloid angiopathy associated with systemic amyloidosis
  • Light chain disease
  • Light chain disease
  • Light chain disease
  • Myeloma-associated amyloidosis
  • Myeloma-associated amyloidosis
  • Primary sporadic amyloid myopathy
  • Primary systemic amyloidosis associated with occult plasma cell dyscrasia
  • Pseudoscleroderma due to amyloid light-chain amyloidosis
  • Scleroderma-like secondary cutaneous sclerosis
  • Sporadic primary amyloidosis
  • Systemic amyloidosis
  • Systemic amyloidosis affecting skin

Clinical Information

  • IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS-. a nonproliferative disorder of the plasma cell characterized by excessive production and misfolding of immunoglobulin light chains that form insoluble amyloid fibrils see amyloid deposits in various tissues. clinical features include liver failure; multiple myeloma; nephrotic syndrome; restrictive cardiomyopathy and neuropathies.
  • AMYLOIDOSIS-. a group of sporadic familial and/or inherited degenerative and infectious disease processes linked by the common theme of abnormal protein folding and deposition of amyloid. as the amyloid deposits enlarge they displace normal tissue structures causing disruption of function. various signs and symptoms depend on the location and size of the deposits.
  • AMYLOIDOSIS FAMILIAL-. diseases in which there is a familial pattern of amyloidosis.
  • AMYLOID NEUROPATHIES FAMILIAL-. inherited disorders of the peripheral nervous system associated with the deposition of amyloid in nerve tissue. the different clinical types based on symptoms correspond to the presence of a variety of mutations in several different proteins including transthyretin prealbumin; apolipoprotein a i; and gelsolin.
  • CEREBRAL AMYLOID ANGIOPATHY FAMILIAL-. a familial disorder marked by amyloid deposits in the walls of small and medium sized blood vessels of cerebral cortex and meninges.

Diagnostic Related Groups

The ICD-10 code E85.89 is grouped in the following groups for version MS-DRG V38.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC).
applicable from 10/01/2020 through 09/30/2021.


Replacement Code

E8589 replaces the following previously assigned ICD-10 code(s):

  • E85.8 - Other amyloidosis

Convert E85.89 to ICD-9

  • 277.39 - Amyloidosis NEC (Approximate Flag)

Code Classification

  • Endocrine, nutritional and metabolic diseases (E00–E90)

Code History

  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021